Actively Recruiting
A Study on the Significance of Joint Evaluation of Gastrointestinal Ultrasound Results and Renal Artery Resistance Index for Assessing the Intestinal-renal Syndrome in Sepsis Patients
Led by Zhangzhou Municipal Hospital · Updated on 2025-02-28
74
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research focuses on adult patients with sepsis caused by abdominal infections, aiming to understand the progression of entero-renal syndrome. The study compares patients who survive with those who do not by examining gastrointestinal function, blood flow in the superior mesenteric artery, and the renal artery resistance index. Researchers seek to provide reliable information to improve clinical decision-making and rescue success rates. Participants undergo ultrasound examinations to measure the gastric antrum cross-sectional area, colon diameter, colon peristalsis frequency, and renal artery resistance index. These measurements are taken at multiple time points: upon ICU admission, and then 6, 24, 48, 72, and 120 hours later. Additional monitoring includes central venous pressure, oxygen saturation, inflammatory markers, blood lactic acid, blood creatinine, fluid intake, and bladder pressure. During the study, participants are monitored closely in the ICU with data collected to assess survival outcomes. The main outcome measures focus on the resistance indices of the superior mesenteric artery and renal artery at admission and at 24 and 72 hours post-admission. This observational study extends up to 120 hours with ongoing assessments to better understand the syndrome’s progression and support clinical care for sepsis patients.
CONDITIONS
Brief Title
A Study of Enterorenal Syndrome Assessed by Gastrointestinal Ultrasound Combined with Renal Artery Resistance Index
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with intra-abdominal infections
- Patients with sepsis or septic shock
- Age between 14 and 85 years
- All genders are eligible
You will not qualify if you...
- Patients with open chest or abdominal injury
- Patients with advanced tumor
- Patients with uremia
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 days (120 hours) during ICU stay
Participants undergo gastrointestinal ultrasound and renal artery resistance index measurements at multiple timepoints while in the ICU to assess enterorenal syndrome.
6 assessment timepoints: at ICU admission (0h), 6h, 24h, 48h, 72h, and 120h
Duration - Up to 28 days
Participants are monitored for up to 28 days to evaluate survival and progression of enterorenal syndrome.
Follow-up visits as per routine clinical care
Trial Site Locations
Total: 1 location
1
Qingjiang Zheng
Zhangzhou, Fujian, China, 363000
Actively Recruiting
Research Team
D
De Kang, Dr.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here